Antitrypanosomal Drug Regimens
| Drug | Age group | Dosage and duration |
| Benznidazole | 2–12 years of age* | 5–8 mg/kg per day orally in 2 divided doses for 60 days |
| Lampit® (nifurtimox) | Birth to younger than 18 years of age, weighing at least 2.5 kg** | Body weight greater than or equal to 40 kg:
8–10 mg/kg per day orally in 3 divided doses for 60 days |
| Body weight less than 40 kg:
10–20 mg/kg per day orally in 3 divided doses for 60 days |
** Lampit® (nifurtimox) is FDA approved for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi in pediatric patients from birth to younger than 18 years (weighing at least 2.5 kg). Use of nifurtimox to treat a patient outside of the FDA-approved age range of birth to younger than 18 years is based on clinical diagnosis and decision by the treating physician under practice of medicine.
